Literature DB >> 1988723

The distribution of residual cancer in radical prostatectomy specimens in stage A prostate cancer.

D R Greene1, S Egawa, G Neerhut, W Flanagan, T M Wheeler, P T Scardino.   

Abstract

To assess the volume and distribution of residual cancer after transurethral resection of the prostate in stage A cancer patients 42 step-sectioned radical prostatectomy specimens were examined, and the volume, location, grade and extracapsular extension of the residual tumor were recorded. A total of 13 patients had stage A1 tumors (5% or less tumor in the transurethral resection specimen and a Gleason sum of 7 or less) and 29 had stage A2 disease. Residual cancer was present in the radical prostatectomy specimen in 41 patients (98%) with a mean volume of 1.28 cc. The location of residual cancer, that is multifocal (76%), peripheral (81%) and distal to the verumontanum (66%), makes complete removal or even identification of residual tumor (restaging) by repeat transurethral resection improbable. Of the stage A1 cancer patients 4 (30%) had more than 1 cc residual tumor volume, extracapsular extension or seminal vesicle invasion. On the other hand, 14 of the stage A2 cancer patients (48%) had less than 1 cc residual tumor completely confined to the gland. Foci of residual cancer were found in the transition zone in 67% and in the peripheral zone in 90% of the patients. The grade of the residual peripheral zone cancer was significantly higher than that of the transition zone cancer in the same gland (p = 0.0004). Eight of 13 instances of extracapsular extension and all 5 of seminal vesicle invasion were directly attributable to peripheral zone cancer. These observations imply that the greatest threat to patients with stage A prostate cancer may be a separate, associated cancer in the peripheral zone rather than the primary transition zone cancer incidentally removed at transurethral resection.

Entities:  

Mesh:

Year:  1991        PMID: 1988723     DOI: 10.1016/s0022-5347(17)38328-3

Source DB:  PubMed          Journal:  J Urol        ISSN: 0022-5347            Impact factor:   7.450


  8 in total

1.  Genetic analysis of prostatic atypical adenomatous hyperplasia (adenosis).

Authors:  J A Doll; X Zhu; J Furman; Z Kaleem; C Torres; P A Humphrey; H Donis-Keller
Journal:  Am J Pathol       Date:  1999-09       Impact factor: 4.307

2.  Incidental prostatic carcinoma. A predictive role of neoangiogenesis and comparison with other prognostic factors.

Authors:  M Volavsek; A Masera; Z Ovcak
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

3.  Tissue shrinkage after fixation with formalin injection of prostatectomy specimens.

Authors:  Sara Jonmarker; Alexander Valdman; Anna Lindberg; Magnus Hellström; Lars Egevad
Journal:  Virchows Arch       Date:  2006-08-15       Impact factor: 4.064

4.  Expression of E-cadherin in primary and metastatic prostate cancer.

Authors:  L Cheng; M Nagabhushan; T P Pretlow; S B Amini; T G Pretlow
Journal:  Am J Pathol       Date:  1996-05       Impact factor: 4.307

5.  Overexpression of Pim-1 during progression of prostatic adenocarcinoma.

Authors:  T L Cibull; T D Jones; L Li; J N Eble; L Ann Baldridge; S R Malott; Y Luo; L Cheng
Journal:  J Clin Pathol       Date:  2006-03       Impact factor: 3.411

6.  The clinical features of anterior prostate cancers.

Authors:  Theresa M Koppie; Fernando J Bianco; Kentaro Kuroiwa; Victor E Reuter; Bertrand Guillonneau; James A Eastham; Peter T Scardino
Journal:  BJU Int       Date:  2006-10-09       Impact factor: 5.588

7.  Diagnosis, prognosis and management of incidentally found prostate cancer.

Authors:  P J Davidson
Journal:  Urol Res       Date:  1993-01

8.  Expression of prostatic acid phosphatase (PSAP) in transurethral resection specimens of the prostate is predictive of histopathologic tumor stage in subsequent radical prostatectomies.

Authors:  Sven Gunia; Stefan Koch; Matthias May; Manfred Dietel; Andreas Erbersdobler
Journal:  Virchows Arch       Date:  2009-03-20       Impact factor: 4.064

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.